

Small Cell Lung Cancer Small Cell Lung Carcinoma

Atezolizumab Consolidation in Limited Stage Small Cell Lung Cancer

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT04308785 ML41257

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04308785 ML41257
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
